These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 1330419)

  • 21. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA; Tayeb OS
    Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates.
    Prosser BL; Beskid G
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):33-45. PubMed ID: 7789095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of CP-74,667. A new fluoroquinolone compared with other quinolones.
    Gu JW; Fang W; Chin NX; Neu HC
    Diagn Microbiol Infect Dis; 1992; 15(7):613-20. PubMed ID: 1330421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin.
    Knapp JS; Hale JA; Neal SW; Wintersheid K; Rice RJ; Whittington WL
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2442-5. PubMed ID: 8585723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative antimicrobial activity and spectrum of CP-99,219, a novel fluoroquinolone, tested against ciprofloxacin-resistant clinical isolates.
    Murphy SP; Cormican MG; Jones RN
    Ir J Med Sci; 1995; 164(4):271-3. PubMed ID: 8522427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of temafloxacin against gram-positive cocci including methicillin-resistant Staphylococcus aureus.
    Fuchs PC
    Am J Med; 1991 Dec; 91(6A):15S-18S. PubMed ID: 1662886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro comparison of E4868, a new trifluoroquinolone, with ciprofloxacin and temafloxacin tested against 5192 recent clinical isolates from five medical centers.
    Murray PR; Jones RN; Washington JA; Gerlach EH; Allen SD
    Diagn Microbiol Infect Dis; 1993; 17(4):307-11. PubMed ID: 8112046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of the new fluoroquinolone CP-99,219.
    Neu HC; Chin NX
    Antimicrob Agents Chemother; 1994 Nov; 38(11):2615-22. PubMed ID: 7872757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS; Mazens-Sullivan MF; Bartlett RC
    Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
    Hosaka M; Yasue T; Fukuda H; Tomizawa H; Aoyama H; Hirai K
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2108-17. PubMed ID: 1332587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of the fluoroquinolone antibiotics.
    Just PM
    Pharmacotherapy; 1993; 13(2 Pt 2):4S-17S. PubMed ID: 8386356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
    Jones RN; Pfaller MA;
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):237-43. PubMed ID: 11404067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci.
    Coque TM; Singh KV; Murray BE
    J Antimicrob Chemother; 1996 May; 37(5):1011-6. PubMed ID: 8737152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
    Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
    Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of temafloxacin against gram-negative bacteria: an overview.
    Hardy DJ
    Am J Med; 1991 Dec; 91(6A):19S-23S. PubMed ID: 1662890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci.
    Korten V; Tomayko JF; Murray BE
    Antimicrob Agents Chemother; 1994 Mar; 38(3):611-5. PubMed ID: 8203863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial activity of a new antipseudomonal dual-action drug, Ro 25-0534.
    Jones RN; Sanchez ML
    Diagn Microbiol Infect Dis; 1994 Jan; 18(1):61-8. PubMed ID: 8026159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.